img

Global Oral Hypoglycemic Agents and Insulin Analogues Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oral Hypoglycemic Agents and Insulin Analogues Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Oral Hypoglycemic Agents and Insulin Analogues report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oral Hypoglycemic Agents and Insulin Analogues market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Drug Store are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oral Hypoglycemic Agents and Insulin Analogues industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Oral Hypoglycemic Agents and Insulin Analogues key manufacturers include Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk, Eli Lilly, Tonghua Dongbao, United Laboratory and Jiangsu Wanbang, etc. Sanofi-Aventis, Ganlee, Biocon are top 3 players and held % sales share in total in 2022.
Oral Hypoglycemic Agents and Insulin Analogues can be divided into Insulin Secretagogues, Alpha-glucosidase Inhibitors and Insulin Sensitizers,, etc. Insulin Secretagogues is the mainstream product in the market, accounting for % sales share globally in 2022.
Oral Hypoglycemic Agents and Insulin Analogues is widely used in various fields, such as Hospitals, Drug Store and Others,, etc. Hospitals provides greatest supports to the Oral Hypoglycemic Agents and Insulin Analogues industry development. In 2022, global % sales of Oral Hypoglycemic Agents and Insulin Analogues went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Hypoglycemic Agents and Insulin Analogues market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Sanofi-Aventis
Ganlee
Biocon
Novo Nordisk
Eli Lilly
Tonghua Dongbao
United Laboratory
Jiangsu Wanbang
Segment by Type
Insulin Secretagogues
Alpha-glucosidase Inhibitors
Insulin Sensitizers

Segment by Application


Hospitals
Drug Store
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oral Hypoglycemic Agents and Insulin Analogues market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oral Hypoglycemic Agents and Insulin Analogues, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oral Hypoglycemic Agents and Insulin Analogues industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oral Hypoglycemic Agents and Insulin Analogues in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oral Hypoglycemic Agents and Insulin Analogues introduction, etc. Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Oral Hypoglycemic Agents and Insulin Analogues market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Oral Hypoglycemic Agents and Insulin Analogues Market Overview
1.1 Oral Hypoglycemic Agents and Insulin Analogues Product Overview
1.2 Oral Hypoglycemic Agents and Insulin Analogues Market Segment by Type
1.2.1 Insulin Secretagogues
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Insulin Sensitizers
1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Type
1.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Overview by Type (2018-2034)
1.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size Review by Type (2018-2024)
1.3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Type (2018-2024)
1.4.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Type (2018-2024)
2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Competition by Company
2.1 Global Top Players by Oral Hypoglycemic Agents and Insulin Analogues Sales (2018-2024)
2.2 Global Top Players by Oral Hypoglycemic Agents and Insulin Analogues Revenue (2018-2024)
2.3 Global Top Players by Oral Hypoglycemic Agents and Insulin Analogues Price (2018-2024)
2.4 Global Top Manufacturers Oral Hypoglycemic Agents and Insulin Analogues Manufacturing Base Distribution, Sales Area, Product Type
2.5 Oral Hypoglycemic Agents and Insulin Analogues Market Competitive Situation and Trends
2.5.1 Oral Hypoglycemic Agents and Insulin Analogues Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Oral Hypoglycemic Agents and Insulin Analogues Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Hypoglycemic Agents and Insulin Analogues as of 2022)
2.7 Date of Key Manufacturers Enter into Oral Hypoglycemic Agents and Insulin Analogues Market
2.8 Key Manufacturers Oral Hypoglycemic Agents and Insulin Analogues Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Oral Hypoglycemic Agents and Insulin Analogues Status and Outlook by Region
3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Region
3.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2018-2024)
3.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Region (2018-2024)
3.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Region
3.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2024-2034)
3.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Region (2024-2034)
3.3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Oral Hypoglycemic Agents and Insulin Analogues by Application
4.1 Oral Hypoglycemic Agents and Insulin Analogues Market Segment by Application
4.1.1 Hospitals
4.1.2 Drug Store
4.1.3 Others
4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Application
4.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Overview by Application (2018-2034)
4.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size Review by Application (2018-2024)
4.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Application (2018-2024)
4.3.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Breakdown by Application (2018-2024)
5 North America Oral Hypoglycemic Agents and Insulin Analogues by Country
5.1 North America Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Country
5.1.1 North America Oral Hypoglycemic Agents and Insulin Analogues Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2018-2024)
5.1.3 North America Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2018-2024)
5.2 North America Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Country
5.2.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2024-2034)
5.2.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2024-2034)
6 Europe Oral Hypoglycemic Agents and Insulin Analogues by Country
6.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Country
6.1.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2018-2024)
6.1.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2018-2024)
6.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Country
6.2.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2024-2034)
6.2.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2024-2034)
7 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues by Region
7.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Region
7.1.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Region
7.2.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Region (2024-2034)
8 Latin America Oral Hypoglycemic Agents and Insulin Analogues by Country
8.1 Latin America Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Country
8.1.1 Latin America Oral Hypoglycemic Agents and Insulin Analogues Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2018-2024)
8.1.3 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2018-2024)
8.2 Latin America Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Country
8.2.1 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2024-2034)
8.2.2 Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2024-2034)
9 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues by Country
9.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Historic Market Size by Country
9.1.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Forecasted Market Size by Country
9.2.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Sanofi-Aventis
10.1.1 Sanofi-Aventis Company Information
10.1.2 Sanofi-Aventis Introduction and Business Overview
10.1.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.1.5 Sanofi-Aventis Recent Development
10.2 Ganlee
10.2.1 Ganlee Company Information
10.2.2 Ganlee Introduction and Business Overview
10.2.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.2.5 Ganlee Recent Development
10.3 Biocon
10.3.1 Biocon Company Information
10.3.2 Biocon Introduction and Business Overview
10.3.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.3.5 Biocon Recent Development
10.4 Novo Nordisk
10.4.1 Novo Nordisk Company Information
10.4.2 Novo Nordisk Introduction and Business Overview
10.4.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.4.5 Novo Nordisk Recent Development
10.5 Eli Lilly
10.5.1 Eli Lilly Company Information
10.5.2 Eli Lilly Introduction and Business Overview
10.5.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.5.5 Eli Lilly Recent Development
10.6 Tonghua Dongbao
10.6.1 Tonghua Dongbao Company Information
10.6.2 Tonghua Dongbao Introduction and Business Overview
10.6.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.6.5 Tonghua Dongbao Recent Development
10.7 United Laboratory
10.7.1 United Laboratory Company Information
10.7.2 United Laboratory Introduction and Business Overview
10.7.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.7.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.7.5 United Laboratory Recent Development
10.8 Jiangsu Wanbang
10.8.1 Jiangsu Wanbang Company Information
10.8.2 Jiangsu Wanbang Introduction and Business Overview
10.8.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Products Offered
10.8.5 Jiangsu Wanbang Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Oral Hypoglycemic Agents and Insulin Analogues Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain Analysis
11.4 Oral Hypoglycemic Agents and Insulin Analogues Market Dynamics
11.4.1 Oral Hypoglycemic Agents and Insulin Analogues Industry Trends
11.4.2 Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
11.4.3 Oral Hypoglycemic Agents and Insulin Analogues Market Challenges
11.4.4 Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Oral Hypoglycemic Agents and Insulin Analogues Distributors
12.3 Oral Hypoglycemic Agents and Insulin Analogues Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Insulin Secretagogues
Table 2. Major Company of Alpha-glucosidase Inhibitors
Table 3. Major Company of Insulin Sensitizers
Table 4. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (K Units)
Table 6. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US& Million)
Table 8. Global Oral Hypoglycemic Agents and Insulin Analogues Market Share in Value by Type (2018-2024)
Table 9. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2018-2024) & (USD/Unit)
Table 10. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2024-2034) & (K Units)
Table 11. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type (2024-2034)
Table 14. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2024-2034) & (USD/Unit)
Table 15. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (K Units)
Table 16. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2018-2024)
Table 18. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2018-2024)
Table 20. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2018-2024)
Table 22. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units) by Type (2018-2024)
Table 24. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Company (2018-2024) & (K Units)
Table 26. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Share by Company (2018-2024)
Table 27. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Company (2018-2024)
Table 29. Global Market Oral Hypoglycemic Agents and Insulin Analogues Price by Company (2018-2024) & (USD/Unit)
Table 30. Global Oral Hypoglycemic Agents and Insulin Analogues Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Hypoglycemic Agents and Insulin Analogues as of 2022)
Table 33. Date of Key Manufacturers Enter into Oral Hypoglycemic Agents and Insulin Analogues Market
Table 34. Key Manufacturers Oral Hypoglycemic Agents and Insulin Analogues Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 37. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2018-2024) & (K Units)
Table 38. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Region (2018-2024)
Table 41. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 42. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2024-2034) & (K Units)
Table 43. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Region (2024-2034)
Table 46. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 47. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 48. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (K Units)
Table 49. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application (2018-2024)
Table 52. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2018-2024) & (USD/Unit)
Table 53. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2024-2034) & (K Units)
Table 54. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application (2024-2034)
Table 57. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2024-2034) & (USD/Unit)
Table 58. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) (K Units)
Table 59. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) (K Units)
Table 61. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) (K Units)
Table 63. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) (K Units)
Table 65. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) (K Units)
Table 67. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (K Units)
Table 69. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2018-2024)
Table 72. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (K Units)
Table 73. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (K Units)
Table 77. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (K Units)
Table 81. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2018-2024) & (K Units)
Table 85. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (K Units)
Table 93. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (K Units)
Table 97. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (K Units)
Table 101. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Country (2024-2034)
Table 108. Sanofi-Aventis Company Information
Table 109. Sanofi-Aventis Introduction and Business Overview
Table 110. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 111. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product
Table 112. Sanofi-Aventis Recent Development
Table 113. Ganlee Company Information
Table 114. Ganlee Introduction and Business Overview
Table 115. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 116. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product
Table 117. Ganlee Recent Development
Table 118. Biocon Company Information
Table 119. Biocon Introduction and Business Overview
Table 120. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 121. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product
Table 122. Biocon Recent Development
Table 123. Novo Nordisk Company Information
Table 124. Novo Nordisk Introduction and Business Overview
Table 125. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 126. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product
Table 127. Novo Nordisk Recent Development
Table 128. Eli Lilly Company Information
Table 129. Eli Lilly Introduction and Business Overview
Table 130. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 131. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product
Table 132. Eli Lilly Recent Development
Table 133. Tonghua Dongbao Company Information
Table 134. Tonghua Dongbao Introduction and Business Overview
Table 135. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 136. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product
Table 137. Tonghua Dongbao Recent Development
Table 138. United Laboratory Company Information
Table 139. United Laboratory Introduction and Business Overview
Table 140. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 141. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product
Table 142. United Laboratory Recent Development
Table 143. Jiangsu Wanbang Company Information
Table 144. Jiangsu Wanbang Introduction and Business Overview
Table 145. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 146. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product
Table 147. Jiangsu Wanbang Recent Development
Table 148. Key Raw Materials Lists
Table 149. Raw Materials Key Suppliers Lists
Table 150. Oral Hypoglycemic Agents and Insulin Analogues Market Trends
Table 151. Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
Table 152. Oral Hypoglycemic Agents and Insulin Analogues Market Challenges
Table 153. Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
Table 154. Oral Hypoglycemic Agents and Insulin Analogues Distributors List
Table 155. Oral Hypoglycemic Agents and Insulin Analogues Downstream Customers
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Product Picture
Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of Insulin Secretagogues
Figure 6. Global Insulin Secretagogues Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of Alpha-glucosidase Inhibitors
Figure 8. Global Alpha-glucosidase Inhibitors Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of Insulin Sensitizers
Figure 10. Global Insulin Sensitizers Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2018-2034) & (US$ Million)
Figure 12. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type in 2022 & 2034
Figure 13. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type in 2022
Figure 14. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type in 2022
Figure 15. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type in 2022
Figure 16. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type in 2022
Figure 19. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Oral Hypoglycemic Agents and Insulin Analogues Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Oral Hypoglycemic Agents and Insulin Analogues Revenue in 2022
Figure 25. Oral Hypoglycemic Agents and Insulin Analogues Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Hospitals
Figure 27. Global Hospitals Sales YoY Growth (2018-2034) & (K Units)
Figure 28. Product Picture of Drug Store
Figure 29. Global Drug Store Sales YoY Growth (2018-2034) & (K Units)
Figure 30. Product Picture of Others
Figure 31. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 32. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2018-2034) & (US$ Million)
Figure 33. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application in 2022 & 2034
Figure 34. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application in 2022
Figure 35. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application in 2022
Figure 36. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application in 2022
Figure 37. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application in 2022
Figure 40. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Oral Hypoglycemic Agents and Insulin Analogues Manufacturing Cost Structure
Figure 45. Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries